Xintela
Xintela is a Swedish clinical-stage biopharma company based in Lund that develops stem cell therapies and targeted cancer therapies built around the cell-surface marker integrin α10β1. Its business includes the XSTEM stem cell platform, an in-house GMP manufacturing facility, and Targinta AB, a wholly owned subsidiary focused on antibody-based oncology programs.
Fiscal year 2025 · change from previous year
Development 2019–2025
Business
Share of revenueXSTEM and related stem cell treatments for human regenerative medicine.
In-house production and development services for cell-based products.
Targinta's preclinical antibody programs targeting integrin α10β1 in cancer.
EQSTEM and other animal stem cell programs for equine and veterinary uses.
Customers
Xintela sells into clinical development, research, and collaboration settings rather than mass commercial healthcare markets. Its direct customers and partners include hospitals, research institutions, biotech collaborators, and potential licensees that need stem cell products, GMP manufacturing, or development rights. In veterinary applications, the customer base extends to animal health partners and product developers.
Buy or collaborate on XSTEM and oncology programs for human clinical and preclinical development.
Use Xintela's facility for process development and manufacturing of cell-based products.
Acquire rights to Xintela's stem cell or antibody technology for commercialization.
Work on EQSTEM and other animal stem cell products for equine indications.
Strategy
Xintela's strategy is to advance XSTEM toward approved therapy status through clinical data, strategic partnerships, and commercialization agreements. At the same time, it uses its GMP facility to generate service revenue and build manufacturing capabilities that can support both internal programs and external cell therapy projects.
Partnerships can accelerate regulatory, clinical, and commercial progress for the lead stem cell asset.
External manufacturing and process development can help fund operations and validate the platform.
The antibody pipeline broadens the technology base and creates optionality beyond stem cells.
Animal health programs can create additional licensing and manufacturing opportunities.
Geography
Xintela is headquartered and operates from Lund, Sweden, with its core laboratory and GMP activities based at Medicon Village. Its clinical and partnering footprint extends beyond Sweden through studies and collaborations in Australia, the United States, and other international markets. Geography matters because the company depends on cross-border clinical development, regulatory pathways, and partner access rather than a single domestic sales market.
Risks
Xintela faces the typical risks of a clinical-stage biotech company: product candidates may fail in development, regulatory pathways may be longer than expected, and commercial adoption may not materialize. The company also depends on external financing and partner support, while its GMP and collaboration model creates execution risk around manufacturing quality, study timelines, and contract revenue.
- Product development failureImpact: CriticalLikelihood: High
XSTEM, TARG9, and TARG10 are still in development and may never reach market.
Exposure: Lead assets and pipeline value
- Financing riskImpact: HighLikelihood: High
The company relies on equity, loans, grants, and collaboration income to fund operations.
Exposure: Corporate continuity and project funding
- Regulatory and clinical riskImpact: HighLikelihood: High
Cell therapies and antibodies require successful trials and approvals across jurisdictions.
Exposure: XSTEM and Targinta programs
- Partner concentration and execution riskImpact: MediumLikelihood: Low
Service revenue and development milestones depend on a limited number of collaborations.
Exposure: GMP operations and licensing income
- Patent and IP riskImpact: MediumLikelihood: Low
The business depends on protecting integrin α10β1-based technology and related families.
Exposure: Platform differentiation and licensing value
Accounting
Judgemental itemsMost clinical and preclinical spending is expensed immediately, which suppresses current earnings but reflects pipeline investment.
Revenue from GMP assignments, licenses, and milestones may be recognized at different points depending on contract terms.
Patent families and technology rights require judgment on useful life, capitalization, and potential impairment.
Operating leases for premises affect reported operating costs and balance sheet commitments.
Disclosure and valuation depend on the company's ability to secure continued funding.
Similar listed companies
Publicly listed companies with a comparable business focus.
XTL Biopharmaceuticals Ltd
XTLB · Pharmaceutical Preparations
XBiotech Inc.
XBIT · Pharmaceutical Preparations
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
NewcelX Ltd.
NCEL · Pharmaceutical Preparations
Intellia Therapeutics, Inc.
NTLA · In Vitro & In Vivo Diagnostic Substances
Intellia Therapeutics is a clinical-stage biopharmaceutical company built around CRISPR-based gene editing and related delivery technologies.
Cantargia
CANTA · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
Last updated: 24/09/2026